{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-025901","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.693909+00:00","generated_at":"2026-05-15T17:20:18.539297+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura Pharma gets $300K more loans from AD Pharma, warns of possible shutdown if no financing by March 2026","bullets":["Received $100,000 loans on Feb 6, Feb 13, and Mar 9, 2026 from Abuse Deterrent Pharma, LLC (AD Pharma), increasing principal balance to $9,894,279.","Note bears interest at 5.25% per annum, with overdue amounts accruing at 7.5%; events of default include bankruptcy, payment failure, and admitted inability to pay debts.","AD Pharma directly owns approximately 65% of Acura's outstanding common stock as of Feb 28, 2026, and is controlled by Mr. Schutte.","If additional financing is not secured by end of March 2026, Acura will need to scale back operations, including furloughs and layoffs, or terminate operations and seek bankruptcy protection.","No assurance of receiving more funds; failure could result in complete loss of shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-025901","json":"https://secwatch.observer/filing/0001104659-26-025901.json","markdown":"https://secwatch.observer/filing/0001104659-26-025901.md","text":"https://secwatch.observer/filing/0001104659-26-025901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/tm268475d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T17:20:18.539297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"170f7250a105369cf5ca8b3625f951765a5baff3","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$100,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"446552f4637e0d2508075c5a62ef120f4d39a139","claim":"ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC valued at $100,000 (effective 2026-02-06).","evidence_excerpt":"On each of February 6, 2026, February 13, 2026 and March 9, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (\"AD Pharma\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Value","value":"$100,000"},{"label":"Effective","value":"2026-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}